Oncotype DX cost effectivity to a Brazilian public hospital

被引：0
|
作者：
Cabello, C. [1 ]
de Andrade, R. N. [1 ]
Cabello, T. F. [1 ]
Teixeira, S. [1 ]
da Costa, L. S. [1 ]
Ramalho, S. [1 ]
机构：
[1] State Univ Campinas UNICAMP, Campinas, SP, Brazil
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P5-15-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-15-04
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Magee equations and oncotype DX®-a perspective
    Rohit Bhargava
    David J. Dabbs
    Breast Cancer Research and Treatment, 2017, 164 : 245 - 246
  • [22] A quality improvement initiative on the utility of the Oncotype DX breast cancer assay in a community hospital
    Iqbal, Sabah
    Desai, Krishna
    Baralo, Bohdan
    Jain, Akhil
    Pereira, Kristal
    Renzu, Mahvish
    Mehta, Vidhi
    Singh, Vartika
    Ramesh, Nithya
    Deshpande, Sohiel
    Keshava, Vinay Edlukudige
    Thirumaran, Rajesh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results
    Press, David J.
    Ibraheem, Abiola
    Dolan, M. Eileen
    Goss, Kathleen H.
    Conzen, Suzanne
    Huo, Dezheng
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 207 - 220
  • [24] Cost Analysis of Hospitalization for COVID-19 in a Brazilian Public Teaching Hospital
    de Sousa, Fernanda Ferreira
    Vieira, Bruno Barbosa
    Reis, Augusto da Cunha
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 34 : 48 - 54
  • [25] Cost effectiveness analysis of Oncotype DX testing in patients with synchronous unilateral primary breast cancer
    Clark, Melanie Jean
    Coggan, James
    Dignam, James J.
    Rao, Ruta D.
    Usha, Lydia
    Kabaker, Katherine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer
    Tsoi, D. T.
    Inoue, M.
    Kelly, C. M.
    Verma, S.
    Pritchard, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results
    David J. Press
    Abiola Ibraheem
    M. Eileen Dolan
    Kathleen H. Goss
    Suzanne Conzen
    Dezheng Huo
    Breast Cancer Research and Treatment, 2018, 168 : 207 - 220
  • [28] Utilization of Oncotype DX testing in a community hospital system: How did this affect patient care?
    Snow, Jennifer
    Halaharvi, Deepa R.
    Pastorino, Alyssa
    Wooster, Meghan
    Dusseau, Brian
    Cripe, Mark H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [29] Cost effectiveness of oncotype Dx for early stage breast cancer; under National Health Insurance
    Kim, Y.
    Kim, K. E.
    Ju, Y. W.
    Lee, E.
    Lee, H. B.
    Moon, H. G.
    Noh, D. Y.
    Han, W.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S31 - S31
  • [30] Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of PatientsWith Ductal Carcinoma In Situ
    Raldow, Ann C.
    Sher, David
    Chen, Aileen B.
    Recht, Abram
    Punglia, Rinaa S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (33) : 3963 - U49
12345